Navigation Links
Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis

WASHINGTON, Oct. 22 /PRNewswire/ -- The preliminary results of the first- ever randomized study to compare OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, with Boston Scientific's Taxus drug-eluting stent in high risk of restenosis patients show comparable efficacy at 30-day and six- month follow-up, reported Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam, at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, in Washington, D.C.

Specifically, six-month clinical follow-up data from the 193-patient, single-center, prospective, single-blind study called TRIAS HR Pilot indicate:

-- No statistically significant difference in the rate of major adverse

cardiac events (MACE)

-- At six-month follow-up, the majority of patients who received a Genous

stent were on single antiplatelet therapy, while the majority of

patients who received a Taxus stent were still on dual antiplatelet


-- One acute stent thrombosis in the Genous arm, while there was one acute,

one subacute and one late stent thrombosis in the Taxus arm

-- More instances of non-target vessel revascularization (non-TVR) in the

Taxus arm

"The much-needed alternative to drug-eluting stents may not be the next- generation drug-eluting stents," said de Winter. "Genous is a very promising, innovative device with a wide range of applications for physicians and many benefits to patients. The results of our pilot study fully support our rationale for the large-scale TRIAS study that will compare Genous to both drug-eluting and bare metal stents."

For the TRIAS HR Pilot, high risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than 2.8 mm) and/or long lesions (greater than 20 mm) and/or chronic total occlusions.

Genous is co

SOURCE Academic Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
2. Biotec Pharmacon Announces Preliminary Results from the Sloan-Kettering Clinical Study
3. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
6. Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA
7. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
8. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
9. ISTA Pharmaceuticals Announces Positive Preliminary Results from Ecabet Sodium Phase IIb Study
10. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
11. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
Post Your Comments:
(Date:7/22/2014)... ST. LOUIS , July 22, 2014  According ... the time their children spend on digital devices. An ... the ages of 10 and 17 estimate they use ... day. However, a separate AOA survey of parents revealed ... use an electronic device for that same amount of ...
(Date:7/22/2014)... July 22, 2014  Vernalis plc (LSE: VER) and Tris ... (POC) for CCP-08, the third programme to achieve ... collaboration. Under this collaboration, POC requires the successful ... pilot comparative study against an immediate release reference ... will make a milestone payment to Tris. ...
(Date:7/22/2014)... PORT WASHINGTON, New York , ... Neue Partnerschaft für umfassenden ... gefährlichen Medikamenteneinwirkungen in Österreich    ... führender Anbieter von geschlossenen Transfersystemen (Closed System ... Medikus , einen Vertriebshändler und ...
Breaking Medicine Technology:Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... 2014 Cloud+MD Office 2.0 ... suite of medical software and services, designed by ... that produces “Actionable Information” to help Independent Physician ... and Billing Services optimize a wide range of ... Greater Efficiency, Noticeable Cost Reductions and Better Patient ...
(Date:7/22/2014)... For the past nine years, the ... working in tandem to help thousands of cancer patients ... care, and help survivors connect to resources dealing with ... their partnership to include referrals from PAF to LIVESTRONG ... other practical, emotional, and financial issues that accompany a ...
(Date:7/22/2014)... Joining Conquer Paralysis Now as its first champion in ... Paralympic silver medalist and quadriplegic Jennifer French. , As a ... a spinal cord injury in 1998. Now, she has joined ... , “People define cure differently,” French said. “For some, it’s ... the image in our minds of what we were like ...
(Date:7/22/2014)... July 22, 2014 Altec Products, ... workflow solutions, announced today their Gold Sponsorship of ... at Mandalay Bay Hotel and Casino in Las Vegas, ... Summit draws thousands interested in taking advantage of the ... to solve business problems and educate themselves on the ...
(Date:7/22/2014)... Bramal LED announced that they will be ... Jr, airing later this year via Discovery Channel. Dates and ... about Bramal LED’s T-10 lamps, which provide over 80,000 hours ... to 70 percent. Bramal LED’s T-10 lamps can be plugged ... or on direct AC voltage, with no need for an ...
Breaking Medicine News(10 mins):Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 3Health News:Bramal LED to be featured in Upcoming Episode of Innovations with Ed Begley, Jr. 2
... joint becomes inflamed. Treatment is often difficult and recovery ... the pain of this common condition. ,Now, an ... with extracorporeal shock wave therapy. During the therapy, ultrasound ... takes two to three 20-minute shock wave treatments to ...
... located at the base of the hair follicle. Hair ... In many people with hair loss, however, // the ... of abnormal follicles entering longer resting phases and producing ... University of Pennsylvania School of Medicine have isolated stem ...
... say there could be a new way to help prevent ... // increase high-density lipoprotein levels, also known as good cholesterol. ... for heart disease. They are commonly used to lower low-density ... target is a low level of good cholesterol. In fact, ...
... Toronto conducted a study to examine whether current procedures ... antibiotics // unnecessarily. Out of an estimated 6.7 million ... Doctors also researched the use of throat cultures and ... who were prompted to seek medical help for their ...
... attention deficit/hyperactivity disorder (ADHD) affects up to 12 percent of ... increased attention problems at age 7 among kids was seen ... toddlers.The study tracked the number of hours kids watched television ... two hours of television a day. Three-year-olds watched about three ...
... warnings from the Food and Drug Administration may leave ... what they claim.// ,Some of the products ... Blocker, and Zone Fat Blocker.Many of these supplements claim ... consumers to lose weight without making any lifestyle changes. ...
Cached Medicine News:
... ALIF Allograft is processed from 100% cortical ... support. The graft is machined with a ... to graft migration. The intermedulary canal accommodates ... ALIF Allografts contain a relief orientation in ...
Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
Williams Micro Discectomy Instruments are designed to be used in the microsurgical treatment of herniated disks....
... Anteater Titanium Microdiscectomy System offers strength ... surgery. The boss anteater titanium microdiscectomy ... intervertebral discs provides for less invasive ... retractor is designed to provide low ...
Medicine Products: